Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK

被引：0
|
作者：
Paul Emery
Marjolijn Van Keep
Steve Beard
Chris Graham
LaStella Miles
Steffen Marc Jugl
Praveen Gunda
Anna Halliday
Helena Marzo-Ortega
机构：
[1] University of Leeds,Leeds Institute of Rheumatic and Musculoskeletal Medicine
[2] NIHR Leeds Biomedical Research Centre,undefined
[3] Leeds Teaching Hospitals NHS Trust,undefined
[4] BresMed Netherlands BV,undefined
[5] BresMed,undefined
[6] RTI Health Solutions,undefined
[7] Novartis Pharma AG,undefined
[8] Novartis Healthcare Private Limited,undefined
[9] Novartis Pharmaceuticals UK Ltd,undefined
来源：
PharmacoEconomics | 2018年 / 36卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1015 / 1027
页数：12
相关论文
共 50 条
  • [31] Secukinumab: A Review in Ankylosing Spondylitis
    Blair, Hannah A.
    DRUGS, 2019, 79 (04) : 433 - 443
  • [32] Improving the treatment of ankylosing spondylitis in the UK
    Keat, Andrew
    Gaffney, Karl
    Marzo-Ortega, Helena
    Cornell, Trish
    MacKay, Kirsten
    Skerrett, Jane
    Van Rossen, Liz
    Wordsworth, B. Paul
    RHEUMATOLOGY, 2011, 50 (11) : 1936 - 1939
  • [33] The cost-effectiveness of infliximab (Remicade®) in the treatment of ankylosing spondylitis in Canada
    Kobelt, G
    Andlin-Sobocki, P
    Maksymowych, WP
    JOURNAL OF RHEUMATOLOGY, 2006, 33 (04) : 732 - 740
  • [34] Cost effectiveness of adalimumab therapy vs. conventional care in the United Kingdom (UK) patients with active ankylosing spondylitis (AS)
    Botteman, M. F.
    Hay, J. W.
    Van Hout, B. A.
    Curry, A.
    Wong, R.
    Luo, M. P.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 207 - 208
  • [35] The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade®)
    Kobelt, G
    Andlin-Sobocki, P
    Brophy, S
    Jönsson, L
    Calin, A
    Braun, J
    RHEUMATOLOGY, 2004, 43 (09) : 1158 - 1166
  • [36] Comparative efficacy and safety of secukinumab and ixekizumab in patients with active ankylosing spondylitis
    Lee, Y. H.
    Song, G. G.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2021, 80 (08): : 776 - 784
  • [37] Effect of secukinumab on bone formation markers in patients with active ankylosing spondylitis
    Sakellariou, Grigorios T.
    Konsta, Maria
    Katsigianni, Ioanna
    Deligeorgakis, Dimitrios
    Zisopoulos, Dimitrios
    Vounotrypidis, Periklis
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2023, 26 (12) : 2603 - 2606
  • [38] Effectiveness and safety of secukinumab in ankylosing spondylitis: real-life data from Midlands Ankylosing Spondylitis Collaboration (MASC)
    Ajibade, Adeola
    Pandian, Haridha
    Jain, Nibha
    Gupta, Latika
    Laxminarayan, Ramasharan
    Moorthy, Arumugam
    Amarasena, Roshan
    Cox, Natasha
    Sapkota, Hem
    Kakade, Girish
    Elamanchi, Srinivasa
    Prabu, Athiveeraramapandian
    Al-Samaraaie, Elaf
    Barkham, Nick
    RHEUMATOLOGY ADVANCES IN PRACTICE, 2022, 7 (01)
  • [39] COST-EFFECTIVENESS ANALYSIS OF SECUKINUMAB IN ANKYLOSING SPONDYLITIS IN BIOLOGIC-NAIVE PATIENTS FROM THE PORTUGUESE PERSPECTIVE
    Laires, P.
    Silva, C.
    Esparteiro, J.
    Fonseca, J. E.
    VALUE IN HEALTH, 2019, 22 : S699 - S699
  • [40] COST-EFFECTIVENESS ANALYSIS OF SECUKINUMAB IN ANKYLOSING SPONDYLITIS IN BIOLOGIC-EXPERIENCED PATIENTS FROM THE PORTUGUESE PERSPECTIVE
    Laires, P. A.
    Silva, C.
    Esparteiro, J.
    Fonseca, J. E.
    VALUE IN HEALTH, 2019, 22 : S697 - S697
12345